IV. 8 When to seek medical help immediately – red flags
The DiffBiome course is largely safe, and most symptoms are mild and transient. There are, however, signs at which you should not be reading a book, but seeking medical help immediately. This chapter goes through these red flags once, clearly – so that you recognise them, and know what to do.
Recurrent Clostridioides difficile[G] infection can most often be managed at home, with the DiffBiome course and patience. Most of the symptoms that arise during treatment are mild and transient: bloating, wind, a temporary change in the stool. There are, however, signs that may conceal a serious, urgent condition – and at these you must not wait. This chapter serves a single purpose: that you know clearly which these "red flags" are, and that if you notice any of them in yourself, you seek medical help immediately, even at a hospital emergency department. This chapter is the most important safety part of the book – it is worth reading even if you are well now, because that way you will recognise trouble when it comes.
The most serious signs – hospital immediately
Some conditions require immediate hospital care, because they can be life-threatening. Such is strong, cramping or continuous abdominal pain, when your abdomen becomes tense, hard and very tender, and perhaps distended – this can be a sign of severe inflammation or dilation of the large bowel. Such is high fever, shivering, confusion or drowsiness, which may indicate that the infection has entered the bloodstream. And such is severe dehydration: if you barely pass urine, you feel dizzy, you are very weak, your mouth is dry, or you cannot keep fluids down because of vomiting.
At these signs there is no deliberating: call a doctor or an ambulance, go to the emergency department. The DiffBiome course does not replace the hospital in such cases – it is hospital care that brings you to safety.
When the stool gives a message
The stool reveals a lot about your condition. Fresh, red blood in the stool, or black, tarry stool always calls for medical attention – do not wait with it; this is a general emergency red flag, not a C. difficile-specific severity criterion. Likewise, if the diarrhoea does not lessen but worsens day by day, with frequent, watery stools, that too is a signal – circulatory collapse, ileus and megacolon are the hallmarks of the fulminant form as defined by the guidelines, and warrant immediate hospital care (Kelly et al. 2021 [005]; McDonald LC 2018 [023]). After the tenth day of the course, persistently loose, unformed stool (6–7 on the Bristol scale[G]) may indicate that the treatment has not brought the expected response – definitely discuss this with your doctor, because the dose may need to be raised or a different preparation chosen.
The distinction is important: in the first days of the course, transient bloating, wind and mild abdominal discomfort are common and normal. The red flag is not this, but blood, high fever, a worsening, uncontrollable condition.
What to do if you see a warning sign
If you recognise one of the red flags, the thing to do is simple: do not look for an explanation, do not wait "one more day", but seek medical help immediately. Call your treating physician, or if they are unavailable and the symptom is serious, go to the emergency department or call an ambulance. Take with you – or tell them – your diary: how many days the infection has lasted, which DiffBiome preparation and what dose you are taking, which LOT, and exactly which symptoms appeared and since when. This information can speed up appropriate care by minutes.
The Clinical protocol guide v7.1 (2026-08-09) sets out a clear override rule: regardless of the calculated SIS score, critical signs – suspected toxic megacolon[G], fulminant colitis[G], severe dehydration, and sepsis criteria – justify immediate hospital admission (IDSA/SHEA 2021 [028]; ACG 2021 [005]). In these cases the intensive protocol belonging to the upper band (HospBiome 5(L) initiation, then 5(XX) continuation) also comes into consideration only in a hospital setting, under medical supervision.
The DiffBiome datasheet (DiffBiome Service Datasheet) divides side effects into two groups. Common and mild: gastrointestinal discomfort, bloating, flatulence, transient diarrhoea or constipation – these typically resolve on their own. Rare but serious: infection and allergic reaction – these require immediate medical assessment. Within the pharmacovigilance framework, every serious adverse event must be reported to the competent authority (EMA/FDA/local).
The Bristol scale serves for the objective monitoring of the stool (Lewis & Heaton 1997 [020]). The target state of the protocol is Bristol 3–4; a persistent 6–7 value after day 10 is classified as an inadequate therapeutic response, and may justify raising the dose (DiffBiome 30(V)+) or switching the preparation. In severe CDI, the survival benefit of early FMT has been documented by a retrospective, single-centre cohort (Hocquart 2018 [160]: n=111, three-month mortality, FMT OR 0.13); there is no randomised trial for this. Management of the fulminant form is in every case a hospital, multidisciplinary decision, not a home one (Carlson 2022 [058]).
Today you have nothing else to do but really commit the red flags to memory. Read them through twice, and put the short list on the fridge or in your phone.
- Write in a well-visible place: strong/tense abdominal pain, high fever, confusion, severe dehydration, fresh blood in the stool;
- Save your treating physician's and the emergency contact in your phone;
- Fluid replacement and the daily dose according to the usual routine;
- Diary: stool count, Bristol, bloody stool, fever, wellbeing.
Today put together a simple sheet that anyone can pick up in case of trouble – whether you or a relative.
- Write down: the onset of the infection, current DiffBiome preparation and dose, LOT number, other medications;
- Put the sheet next to your diary, in an easily accessible place;
- Tell a relative where to find the sheet if you become unwell;
- Diary: the usual fields + any unusual symptom.
Today review the week's diary from the perspective of whether any worrying sign appeared – and if so, discuss it with your doctor.
- Review: was there bloody stool, fever, worsening diarrhoea or strong abdominal pain during the week?;
- If anything is yes, report it to your doctor even if it has since passed;
- Confirm in your mind the difference: a mild, transient symptom vs. a red flag;
- Diary: the trend of the 3 days, and the weekly summary of the warning signs.
🍽️ Eating during these days
The theme of this chapter is safety and recognising warning signs – here eating works in the background, quietly, for recovery: the varied, fibre-rich plate feeds the engrafted flora and strengthens colonisation resistance[G]. Important, however, is the distinction that the chapter also emphasises: in the first days of the course, transient bloating, wind or mild abdominal discomfort are common and normal – this can also be caused by a new, fermentable plant source – whereas bloody stool, high fever or a worsening condition are a red flag, not a response to food. The concrete eating task for the three days: keep up fluid replacement, and each day include the plant of the day in at least one meal.
For these days (82–84), the Plant Calendar (Appendix F) brings the sources linseed oil (82), pumpkin seed oil (83) and parsley leaf (84). Linseed oil provides omega-3[G] fatty acids, pumpkin seed oil provides zinc and polyphenols[G], and parsley leaf provides vitamin C and plant variety. In the second half of the programme (roughly days 61–90), the goal is to sustain full diversity[G] and fermentable fibre sources: the more kinds of plant source and healthy fat that reach the plate, the more kinds of useful bacteria you feed, and the more short-chain fatty acids[G] (including butyrate[G]) form, which support the gut barrier and diversity. A diverse, stable flora is the basis of resilience – it is what makes the gut more resistant. If one of the sources causes bloating or discomfort, that is not in itself a warning sign; but if you see any of the red flags listed in the chapter, that is not an eating question – seek medical help immediately.
To recognise the red flags, track these fields with particular care:
- daily stool count (and its direction: decreasing / stagnant / increasing);
- stool Bristol scale (1–7);
- bloody stool (yes/no);
- fever (yes/no; if yes: temperature);
- abdominal pain intensity (0–5);
- signs of dehydration (amount of urine, dizziness, weakness);
- fluid intake (litres);
- wellbeing (1–5);
- Movement: type + minutes, step count (target/actual);
- Stress level (1–5) and mood (1–5);
- Sleep (hours + quality 1–5).
Do not wait if you experience any of the following: strong, cramping or continuous abdominal pain, a tense, hard, tender or distended abdomen; high fever or shivering; confusion, drowsiness; signs of dehydration (you barely pass urine, dizziness, marked weakness, dry mouth, or you cannot keep fluids down); fresh, red blood or black, tarry stool; or if you feel so unwell that you cannot get up. These require urgent medical, often hospital, care. Call your treating physician, or in a serious case go to the emergency department or call an ambulance.
Why does this matter?
Knowing the red flags is not scaremongering, but the guarantee of your safety. With the DiffBiome course most symptoms are mild and passing – but recognising the few serious signs can come down to minutes, and those minutes count. If you know what to watch for and what to do, you can move along the road of recovery with peace of mind, because you have a safety net.
References
[005] Kelly C, Fischer M, Allegretti J, LaPlante K, Stewart D, Limketkai B, Stollman N. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. The American journal of gastroenterology. 2021. Link
According to the 2021 ACG guideline, FMT is part of standard care for rCDI; strongly recommended after ≥2 recurrences — American College of Gastroenterology's latest CDI guidelines: FMT strongly recommended after ≥2 CDI recurrences; capsule and colonoscopic administration are equivalent; detailed donor screening and storage protocol; COVID-era updates regarding FMT safety also incorporated.
[020] Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scandinavian Journal of Gastroenterology. 1997. Link
The original validation of the Bristol Stool Form Scale. Whole-gut transit time was measured with radio-opaque marker pellets in 66 volunteers, who kept a diary of stool form on a 7-point scale and of defecation frequency. Transit time correlated most closely with stool form (r = -0.54), more strongly than with stool frequency or stool output. When transit time was altered with senna and with loperamide, stool form tracked the change (r = -0.65). Conclusion: recording stool form is a simple and responsive way to monitor change in bowel function — which is why it is suitable for the patient's own diary.
[023] McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC et al. Clinical Practice Guidelines for Clostridium. difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases. 2018. Link
Comprehensive IDSA/SHEA clinical practice guideline on the diagnosis, treatment and prevention of C. difficile infection in adults and children. It defines severity categories (non-severe, severe, fulminant) and characterises fulminant disease by hypotension or shock, ileus or toxic megacolon — findings that require inpatient care, intravenous therapy and surgical consultation. For multiply recurrent infection in which antibiotic therapy has repeatedly failed, faecal microbiota transplantation is recommended. This document provides the international frame to which the book's red flags and hospital-referral signs are aligned.
[028] Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clinical Infectious Diseases. 2021. Link
A focused update of the 2017 IDSA/SHEA guideline, limited to treatment recommendations. The principal change is that fidaxomicin is now preferred over vancomycin for an initial episode — a conditional recommendation with moderate certainty — because although initial cure is similar, sustained cure is better. For recurrent episodes fidaxomicin is likewise preferred, as is a tapered and pulsed vancomycin regimen. Bezlotoxumab is offered as an adjunct for patients at high risk of recurrence. The guideline states explicitly that vancomycin remains an acceptable choice where fidaxomicin is unavailable, and metronidazole has receded even for mild disease. For the SIS the guideline matters because it confirms that the treatment decision depends not only on current severity but on the risk of recurrence — the duality that underlies the acute and prognostic subscores of the SIS.
[058] Carlson TJ, Gonzales-Luna AJ, Garey KW. Fulminant Clostridioides difficile Infection: A Review of Treatment Options for a Life-Threatening Infection. Semin Respir Crit Care Med. 2022. Link
A review of the treatment options for fulminant Clostridioides difficile infection. The authors put the fulminant form at 3–5% of all CDI cases and its associated mortality at 30–40% — an order of magnitude above CDI mortality at population level. The review works through the pharmacological and surgical options for managing the fulminant case. In this document the item supplies the mortality figure for the terminal station of Section II. 1.; its denominator is all fulminant cases, not only the patients who proceed to surgery.
[160] Hocquart M, Lagier JC, Cassir N, Saidani N, Eldin C, Kerbaj J, Delord M, Valles C, Brouqui P, Raoult D, Million M. Early Fecal Microbiota Transplantation Improves Survival in Severe Clostridium difficile Infections. Clin Infect Dis. 2018. Link
Retrospective cohort study (Marseille, North University Hospital, 2013–2016) of whether **early FMT** improves survival in hospitalised CDI patients, particularly in severe infection. 111 patients: 66 FMT, 45 non-FMT. The primary endpoint was **3-month mortality**. Independent predictors: O27 ribotype (OR 3.64), severe CDI (OR 9.62) and FMT (OR 0.13 — protective). FMT reduced mortality **in severe cases** (OR 0.08; NNT = 2 to save one life at 3 months) but **not in non-severe** cases (OR 1.07). The authors conclude early FMT should be considered first-line for severe CDI. **LIMITATION:** single-centre retrospective cohort; no surgical patients; the effect appeared only in the severe subgroup — hence this is a hospital, not a home, decision, which the handbook stresses.